A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Autoimmune Disorders And Advanced Malignancies
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Diagnosis of Dermatomyositis (DM)/Systematic Sclerosis (SSc), Rheumatoid Arthritis (RA), Systematic Lupus Erythematosus (SLE), Inflammatory Bowel Disease (IBD), Multiple Sclerosis (MS), Sjogren’s syndrome, or other autoimmune diseases. 2) Patients must have histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable. 3) Patients must have normal organ and marrow function. 4) Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment.

You may not be eligible for this study if the following are true:

  • 1) Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from AEs due to agents administered more than 4 weeks earlier have not resolved or stabilized. 2) Patients with prior therapy with an anti-PD-1 or anti-PD-L1. 3) Patients with prior allogeneic hematologic transplant. 4) Patients who are receiving any other investigational agents.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.